Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 2 de 2
Add filters

Document Type
Year range
Biomedical and Pharmacology Journal ; 15(3):1745-1749, 2022.
Article in English | EMBASE | ID: covidwho-2090940


Hospital workers were at high risk for SARS-Cov-2 infection and the first population with authorized access to the three doses of vaccination against SARS-Cov-2 antigen. The study was aimed to compare SARS-Cov-2 antibody levels among hospital workers receiving the three doses of Covid-19 vaccines with a history of Covid-19 infection versus those without a history of infection. A cross sectional study was conducted at the Sulianti Saroso infectious Disease Hospital (SSiDH) in December 2021. The inclusion criteria were hospital workers in both subjects with and without previous Covid-19 infection and those who had received 3 doses of Covid-19 vaccines. Anti SARS-Cov-2 antibody levels measured by the Architect of SARS-Cov-2 igG ii Quant. There were 75 participants in the study, the median of anti SARS Cov-2 levels reported 8724.4 AU/mL (3396.8, 15773.2 AU/mL, interquartile range). They were divided into 2 groups according to the status of prior Covid-19 infection, hospital workers with and without previous of Covid-19 infection. There was no significance difference in antibody less than 25.000 AU/mL between hospital worker with and without previous Covid-19 infection (p=1,000). Meanwhile, the median of antibody levels was seen in the interval between the 3rd dose of vaccine within 1 month;2 to 3 months;4 to 5 months before the antibody measurement (14576.5 AU/mL;12407.4 AU/mL;5778.1 AU/mL, respectively). in this study, after three doses of Covid-19 vaccines, there was no significance difference in antibody levels of hospital worker with and without previous Covid-19 infection. Copyright © 2022 Oriental Scientific Publishing Company. All rights reserved.

Biomedical and Pharmacology Journal ; 14(4):2327-2335, 2021.
Article in English | EMBASE | ID: covidwho-1636627


Coronavirus disease 2019 (COVID-19) was declared as a world pandemic since early 2020. There was no specific antiviral agent that appeared to be active against the virus, and antiviral agent such as remdesivir, favipiravir were in limited supply. We evaluated the use of convalescent plasma (CP) administered as adjuctive treatment to standard of care in moderate to severe COVID-19 patients. We conducted a series of 9 moderate to severe patients of COVID-19 older than 18 years received CP transfusion from 9 recovered donors at a single institution (Sulianti Saroso Infectious Disease Hospital, Jakarta, Indonesia) from January 2021 to June 2021. Out of 9 patients (age range 30-81 years, 6 males and 3 female), and all patients received at least 1 or 2 unit of 200 mL of CP from 9 recovered donors. There were 4 patients (age range 30-71 years, 4 male) that were not treated with antiviral therapy. Of the 9 patients, 2 severe cases were died, while all of moderate cases survived and they were discharged from the hospital (length of stay: 8-22 days). Our experience showed that CP transfusion in moderate COVID-19 patients might provide clinical benefit and it was well-tolerated. However, further development clinical trials with better designs and greater power is needed to evaluate the efficacy and safety of this treatment.